Adjuvanted RSVpreF3 Vaccine for Respiratory Syncytial Virus Prevention in the United Kingdom, Spain, and Australia: A Climate Change Impact Analysis
Author(s)
Anna Puggina, PhD1, Eleftherios Zarkadoulas, PhD2, James Clark-Wright, BSc, MBiochem, MSc, FRSPH3, Sohaib Ashraf, MPharm, MSc3, ANDREA GARCIA I LURI, MSc4, Masnoon Saiyed, MPharm, MS5, Weiwei Xu, MD, PhD6, Shanky Varghese, BE, MBA7, Rachel Castle, BA, GradDip3, Chloe Cross, BA3, Ashwanee A, BA, MSc8, Chelsea Cormack, MEng9, Nidhi Dani, MBA10, Melissa Pegg, BSc, MSc11.
1GSK, Verona, Italy, 2GSK, Wavre, Belgium, 3GSK, London, United Kingdom, 4GSK, Madrid, Spain, 5GSK, Victoria, Australia, 6IQVIA, Amsterdam, Netherlands, 7IQVIA, Bengaluru, India, 8GSK, Oslo, Norway, 9GSK, Montrose, United Kingdom, 10GSK, Zug, Switzerland, 11York Health Economics Consortium, York, United Kingdom.
1GSK, Verona, Italy, 2GSK, Wavre, Belgium, 3GSK, London, United Kingdom, 4GSK, Madrid, Spain, 5GSK, Victoria, Australia, 6IQVIA, Amsterdam, Netherlands, 7IQVIA, Bengaluru, India, 8GSK, Oslo, Norway, 9GSK, Montrose, United Kingdom, 10GSK, Zug, Switzerland, 11York Health Economics Consortium, York, United Kingdom.
OBJECTIVES: Alleviating the burden of vaccine-preventable diseases may directly improve health outcomes and reduce carbon dioxide equivalent (CO2e) emissions generated by healthcare systems, thereby indirectly improving public health. This analysis measured the potential climate change impact (measured as CO2e emissions) of a single-dose respiratory syncytial virus (RSV) vaccination programme using the adjuvanted RSVPreF3 vaccine among older adults (OA) aged ≥60 years in 3 countries.
METHODS: A static, multi-cohort Markov model with a 5-year time horizon, corresponding to protection for 5 consecutive RSV seasons, was used to estimate the climate change impact of the adjuvanted RSVPreF3 vaccine, in comparison with no vaccination, among OA in the United Kingdom (UK; base-case), Spain and Australia (context scenario analyses). Different target populations were considered for each country. Demographic, epidemiological and CO2e emissions data were derived and calculated from national databases and scientific literature. Vaccine efficacy and waning inputs were based on results from the AReSVi-006 Phase 3 trial. In the base-case analysis, a vaccine coverage rate of 70% was assumed. Analyses for Spain and Australia are ongoing and planned for presentation in the poster.
RESULTS: Compared with no vaccination, preliminary analyses from the base-case scenario indicated that a single dose of the adjuvanted RSVPreF3 vaccine for OA aged ≥60 years reduced the number of RSV-lower respiratory tract disease events and associated complications by 37% over a 5-year period, thereby potentially reducing CO2e emissions.
CONCLUSIONS: A single-dose adjuvanted RSVPreF3 vaccination programme for OA aged ≥60 years in the UK could reduce the CO2e emissions associated with RSV treatment and management over 5 years, suggesting that RSV vaccination improves public health and healthcare-related climate change impact. This evidence may inform policymakers and payers of the wider societal benefits of implementing RSV prevention programmes. Broader environmental considerations, such as human health impacts, water footprint and antimicrobial resistance mitigation, will be crucial for planetary stability.
METHODS: A static, multi-cohort Markov model with a 5-year time horizon, corresponding to protection for 5 consecutive RSV seasons, was used to estimate the climate change impact of the adjuvanted RSVPreF3 vaccine, in comparison with no vaccination, among OA in the United Kingdom (UK; base-case), Spain and Australia (context scenario analyses). Different target populations were considered for each country. Demographic, epidemiological and CO2e emissions data were derived and calculated from national databases and scientific literature. Vaccine efficacy and waning inputs were based on results from the AReSVi-006 Phase 3 trial. In the base-case analysis, a vaccine coverage rate of 70% was assumed. Analyses for Spain and Australia are ongoing and planned for presentation in the poster.
RESULTS: Compared with no vaccination, preliminary analyses from the base-case scenario indicated that a single dose of the adjuvanted RSVPreF3 vaccine for OA aged ≥60 years reduced the number of RSV-lower respiratory tract disease events and associated complications by 37% over a 5-year period, thereby potentially reducing CO2e emissions.
CONCLUSIONS: A single-dose adjuvanted RSVPreF3 vaccination programme for OA aged ≥60 years in the UK could reduce the CO2e emissions associated with RSV treatment and management over 5 years, suggesting that RSV vaccination improves public health and healthcare-related climate change impact. This evidence may inform policymakers and payers of the wider societal benefits of implementing RSV prevention programmes. Broader environmental considerations, such as human health impacts, water footprint and antimicrobial resistance mitigation, will be crucial for planetary stability.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE41
Topic
Economic Evaluation, Epidemiology & Public Health, Health Service Delivery & Process of Care
Topic Subcategory
Novel & Social Elements of Value
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Vaccines